Ionis notifies release of update on eplontersen Phase 3 ATTR-CM trial results

• Ionis posted an update on its CARDIO-TTRansform Phase 3 trial of eplontersen in adults with ATTR-CM.
• Trial missed the primary endpoint versus placebo on a composite of CV mortality and recurrent CV events through Week 140.
• Prespecified monotherapy subgroup showed a nominally significant hazard ratio of 0.71; no effect seen in baseline stabilizer users.
• Safety profile remained favorable; full results slated for presentation at the ESC Congress in August 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-028092), on July 09, 2026, and is solely responsible for the information contained therein.